Gabapentin

Generic Name
Gabapentin
Brand Names
Gralise, Neurontin
Drug Type
Small Molecule
Chemical Formula
C9H17NO2
CAS Number
60142-96-3
Unique Ingredient Identifier
6CW7F3G59X
Background

Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages ...

Indication

In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or...

Associated Conditions
Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia
Associated Therapies
-
Clinical Trials
Related News

A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

Phase 3
Completed
Conditions
Transient Insomnia
Interventions
Drug: Placebo
Drug: Gabapentin
First Posted Date
2008-04-25
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
309
Registration Number
NCT00666770
Locations
🇺🇸

Pfizer Investigational Site, New York, New York, United States

A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

Phase 3
Completed
Conditions
Transient Insomnia
Interventions
Drug: Gabapentin
Drug: Placebo
First Posted Date
2008-04-25
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
784
Registration Number
NCT00667108
Locations
🇺🇸

Pfizer Investigational Site, Dallas, Texas, United States

A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness

Phase 3
Completed
Conditions
Transient Insomnia
Interventions
Drug: Placebo
Drug: Gabapentin
First Posted Date
2008-04-25
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
2105
Registration Number
NCT00666575
Locations
🇺🇸

Pfizer Investigational Site, West Jordan, Utah, United States

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

First Posted Date
2008-04-25
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
20
Registration Number
NCT00666796
Locations
🇺🇸

Pfizer Investigational Site, Miami, Florida, United States

A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance

Phase 3
Completed
Conditions
Transient Insomnia
Interventions
Drug: Gabapentin
Drug: Placebo
First Posted Date
2008-04-25
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
773
Registration Number
NCT00666939
Locations
🇺🇸

Pfizer Investigational Site, Johnstown, Pennsylvania, United States

A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment

Phase 3
Completed
Conditions
Transient Insomnia
Interventions
Drug: Gabapentin
First Posted Date
2008-04-16
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
1254
Registration Number
NCT00659100
Locations
🇺🇸

Pfizer Investigational Site, Richmond, Virginia, United States

Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans

First Posted Date
2008-04-09
Last Posted Date
2011-04-25
Lead Sponsor
University of Arkansas
Target Recruit Count
102
Registration Number
NCT00654953
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy

Phase 4
Completed
Conditions
Diabetic Neuropathies
Interventions
Drug: gabapentin
First Posted Date
2008-03-27
Last Posted Date
2021-02-02
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
95
Registration Number
NCT00644748
Locations

Pfizer Investigational Site

A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy

First Posted Date
2008-03-13
Last Posted Date
2013-08-12
Lead Sponsor
Janssen Korea, Ltd., Korea
Target Recruit Count
162
Registration Number
NCT00634543

How Does Gabapentin Affects Post-operative Tonsillectomy Pain?

Phase 3
Completed
Conditions
Post-operative Pain
Interventions
Drug: Gabapentin
Drug: Placebo
First Posted Date
2008-02-27
Last Posted Date
2009-08-18
Lead Sponsor
University of British Columbia
Target Recruit Count
28
Registration Number
NCT00624455
Locations
🇨🇦

BC Children's Hospital, Vancouver, British Columbia, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy